Terramycin

(Oxytetracycline/ Cyclophosphamide)

ApprovedSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Terramycin is one of 40 small molecule programs targeting Combination Therapy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Combination TherapyNot yet recruiting

Combination TherapyApproved

Not yet recruiting

Competition

Competitive Landscape

48 competitors in Combination Therapy

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

1 2

Avastin

Roche

Phase 2

5 3

Liposomal Doxorubicin

Eli Lilly

Phase 3

1 4

Taxol

Teva

Phase 2

3 5

Beyfortus

BeiGene

Phase 2

3 6

Keytruda

Merck & Co.

Phase 2

3 7

Braftovi

Pfizer

Phase 2

1 8

Cabometyx

Bristol-Myers Squibb

Phase 2

1 9

Abraxane

Bristol-Myers Squibb

Phase 2

1 10

Terramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2045

Post-ApprovalNot yet recruiting

Combination Therapy

NCT03892330

Clinical

Trials by Indication[1]

Combination Therapy1 trial

Combination Therapy of Anthracyclines for Children With Nephroblastoma

Not yet recruiting·SShengjing Hospital·Phase 4·NCT03892330·120 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TERRAMYCIN

NDA NDA050286

Jan 1, 1982

TERRAMYCIN

NDA NDA050287

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oxytetracycline/ Cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxytetracycline/ Cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxytetracycline/ Cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA050286). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Terramycin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2045

Trials by Indication[1]

Combination Therapy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News